Top

Published in:

01-09-2014

Bone-targeting agents in prostate cancer

Authors: Daniel L. Suzman, Sosipatros A. Boikos, Michael A. Carducci

Published in: Cancer and Metastasis Reviews | Issue 2-3/2014

Abstract

Bone metastases are present in the vast majority of men with advanced prostate cancer, representing the main cause for morbidity and mortality. Recurrent or metastatic disease is managed initially with androgen deprivation but the majority of the patients eventually will progress to castration-resistant prostate cancer, with patients developing bone metastases in most of the cases. Survival and growth of the metastatic prostate cancer cells is dependent on a complex microenvironment (onco-niche) that includes the osteoblasts, the osteoclasts, the endothelium, and the stroma. This review summarizes agents that target the pathways involved in this complex interaction between prostate cancer and bone microenvironment and aim to transform lethal metastatic prostate cancer into a chronic disease.

Tannock, I. F., de Wit, R., Berry, W. R., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England Journal of Medicine, 351(15), 1502–1512.PubMedCrossRef

Kantoff, P. W., Higano, C. S., Shore, N. D., et al. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England Journal of Medicine, 363(5), 411–422.PubMedCrossRef

de Bono, J. S., Oudard, S., Ozguroglu, M., et al. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. The Lancet, 376(9747), 1147–1154.CrossRef

Parker, C., Nilsson, S., Heinrich, D., et al. (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. The New England Journal of Medicine, 369(3), 213–223.PubMedCrossRef

Fizazi, K., Scher, H. I., Molina, A., et al. (2012). Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology, 13, 983–992.PubMedCrossRef

Scher, H. I., Fizazi, K., Saad, F., et al. (2012). Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study. Journal of Clinical Oncology, 30(Suppl 5), 1.

Paget, S. (1889). The distribution of secondary growths in cancer of the breast. The Lancet, 133(3421), 571–573.CrossRef

Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., & Martin, T. J. (1999). Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocrine Reviews, 20(3), 345–357.PubMedCrossRef

Wada, T., Nakashima, T., Hiroshi, N., & Penninger, J. M. (2006). RANKL–RANK signaling in osteoclastogenesis and bone disease. Trends in Molecular Medicine, 12(1), 17–25.PubMedCrossRef

10.

Shiozawa, Y., Pedersen, E. A., Havens, A. M., et al. (2011). Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. The Journal of Clinical Investigation, 121(4), 1298.PubMedCentralPubMedCrossRef

11.

Pedersen, E. A., Shiozawa, Y., Pienta, K. J., & Taichman, R. S. (2012). The prostate cancer bone marrow niche: more than just ‘fertile soil’. Asian Journal of Andrology, 14(3), 423–427.PubMedCentralPubMedCrossRef

12.

Schneider, A., Kalikin, L. M., Mattos, A. C., et al. (2005). Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology, 146(4), 1727–1736.PubMedCrossRef

13.

Shiozawa, Y., Pedersen, E. A., Patel, L. R., et al. (2010). GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia (New York, NY), 12(2), 116.

14.

Taichman, R. S., Patel, L. R., Bedenis, R., et al. (2013). GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. PloS one, 8(4), e61873.PubMedCentralPubMedCrossRef

15.

Loberg, R. D., Gayed, B. A., Olson, K. B., & Pienta, K. J. (2005). A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell–microenvironment interactions. Journal of Cellular Biochemistry, 96(3), 439–446.PubMedCrossRef

16.

Guise, T. A., Mohammad, K. S., Clines, G., et al. (2006). Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clinical cancer research, 12(20), 6213s–6216s.PubMedCrossRef

17.

Small, E. J., Smith, M. R., Seaman, J. J., Petrone, S., & Kowalski, M. O. (2003). Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. Journal of Clinical Oncology, 21(23), 4277–4284.PubMedCrossRef

18.

Saad, F., Gleason, D. M., Murray, R., et al. (2004). Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. Journal of the National Cancer Institute, 96(11), 879–882.PubMedCrossRef

19.

Rosen, L. S., Gordon, D., Kaminski, M., et al. (2003). Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer, 98(8), 1735–1744.PubMedCrossRef

20.

Smith, M. R., Halabi, S., Ryan, C. J., et al. (2013). Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). ASCO Meeting Abstracts, 31(6_suppl), 27.

21.

Wirth, M., Tammela, T., Huland, H., et al. (2008). Zoledronic acid for the prevention of bone metastases in high risk prostate cancer patients. A randomised, open label, multicentre study of the European Association of Urology (EAU) in cooperation with the Scandinavian Prostate Cancer Group (SPCG) and the Arbeitsgemeinschaft Urologische Onkologie (AUO). European Urology Supplements, 7(3), 232.CrossRef

22.

Smith, M. R., Egerdie, B., Toriz, N. H., et al. (2009). Denosumab in men receiving androgen-deprivation therapy for prostate cancer. The New England Journal of Medicine, 361(8), 745–755.PubMedCentralPubMedCrossRef

23.

Fizazi, K., Lipton, A., Mariette, X., et al. (2009). Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology, 27(10), 1564–1571.PubMedCrossRef

24.

Fizazi, K., Carducci, M., Smith, M., et al. (2011). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. The Lancet, 377(9768), 813–822.CrossRef

25.

Smith, M. R., Saad, F., Coleman, R., et al. (2012). Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. The Lancet, 379(9810), 39–46.CrossRef

26.

Summary minutes of the Oncologic Drugs Advisory Committee meeting. 2012.

27.

Silberstein, E. B. (1996). Dosage and response in radiopharmaceutical therapy of painful osseous metastases. Journal of Nuclear Medicine, 37(2), 249–252.PubMed

28.

Tu, S., Millikan, R. E., Mengistu, B., et al. (2001). Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. The Lancet, 357(9253), 336–341.CrossRef

29.

Sartor, O., Reid, R. H., Bushnell, D. L., Quick, D. P., & Ell, P. J. (2007). Safety and efficacy of repeat administration of samarium Sm–153 lexidronam to patients with metastatic bone pain. Cancer, 109(3), 637–643.PubMedCrossRef

30.

Fizazi, K., Beuzeboc, P., Lumbroso, J., et al. (2009). Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. Journal of Clinical Oncology, 27(15), 2429–2435.PubMedCrossRef

31.

James, N. D., Pirrie, S., Barton, D., et al. (2013). Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747). ASCO Meeting Abstracts, 31(18_suppl), LBA5000.

32.

Nilsson, S., Franzén, L., Parker, C., et al. (2007). Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. The Lancet Oncology, 8(7), 587–594.PubMedCrossRef

33.

Nilsson, S., Strang, P., Aksnes, A. K., et al. (2012). A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. European Journal of Cancer, 48(5), 678–686.PubMedCrossRef

34.

Morris, M. J., Hammers, H. J., Sweeney, C., et al. (2013). Safety of radium-223 dichloride (ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): a phase I prostate cancer clinical trials consortium study. ASCO Meeting Abstracts, 31(15_suppl), 5021.

35.

Carducci, M. A., Padley, R. J., Breul, J., et al. (2003). Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. Journal of Clinical Oncology, 21(4), 679–689.PubMedCrossRef

36.

Schelman, W. R., Liu, G., Wilding, G., Morris, T., Phung, D., & Dreicer, R. (2011). A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Investigational New Drugs, 29(1), 118–125.PubMedCentralPubMedCrossRef

37.

James, N. D., Caty, A., Payne, H., et al. (2010). Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration–resistant prostate cancer and bone metastases who were pain–free or mildly symptomatic for pain: a double–blind, placebo–controlled, randomized phase II trial. BJU International, 106(7), 966–973.PubMedCrossRef

38.

Nelson, J. B., Love, W., Chin, J. L., et al. (2008). Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone–refractory prostate cancer. Cancer, 113(9), 2478–2487.PubMedCentralPubMedCrossRef

39.

Nelson, J. B., Fizazi, K., Miller, K., et al. (2012). Phase 3, randomized, placebo–controlled study of zibotentan (ZD4054) in patients with castration–resistant prostate cancer metastatic to bone. Cancer, 118(22), 5709–5718.PubMedCrossRef

40.

Miller, K., Moul, J., Gleave, M., et al. (2013). Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer. Prostate cancer and prostatic diseases, 16(2), 187–192.PubMedCrossRef

41.

Akhavan, A., McHugh, K. H., Guruli, G., et al. (2006). Endothelin receptor A blockade enhances taxane effects in prostate cancer. Neoplasia, 8(9), 725–732.PubMedCentralPubMedCrossRef

42.

Kim, L. C., Song, L., & Haura, E. B. (2009). Src kinases as therapeutic targets for cancer. Nature Reviews Clinical Oncology, 6(10), 587–595.PubMedCrossRef

43.

Summy, J. M., & Gallick, G. E. (2003). Src family kinases in tumor progression and metastasis. Cancer and Metastasis Reviews, 22(4), 337–358.PubMedCrossRef

44.

Edwards, J. (2010). Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer. Expert Opinion on Investigational Drugs, 19(5), 605–614.PubMedCrossRef

45.

Tatarov, O., Mitchell, T. J., Seywright, M., Leung, H. Y., Brunton, V. G., & Edwards, J. (2009). SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clinical Cancer Research, 15(10), 3540–3549.PubMedCrossRef

46.

Nam, S., Kim, D., Cheng, J. Q., et al. (2005). Action of the src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Research, 65(20), 9185–9189.PubMedCrossRef

47.

Brownlow, N., Mol, C., Hayford, C., Ghaem-Maghami, S., & Dibb, N. (2008). Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia, 23(3), 590–594.PubMedCrossRef

48.

Lee, Y., Huang, C., Murshed, M., Chu, K., Araujo, J. C., & Ye, X. (2010). Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene, 29(22), 3196–3207.PubMedCentralPubMedCrossRef

49.

Araujo, J. C., Trudel, G. C., Saad, F., Armstrong, A. J., Yu, E. Y., Bellmunt, J., et al. (2013). Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol, 14(13), 1307–1316.

50.

Araujo, J. C., Mathew, P., Armstrong, A. J., et al. (2012). Dasatinib combined with docetaxel for castration–resistant prostate cancer. Cancer, 118(1), 63–71.PubMedCentralPubMedCrossRef

51.

Anderson, G., Gries, M., Kurihara, N., et al. (2006). Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood, 107(8), 3098–3105.PubMedCrossRef

52.

Efstathiou, E., Troncoso, P., Wen, S., et al. (2007). Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clinical Cancer Research, 13(4), 1224–1231.PubMedCrossRef

53.

Vallet, S., Palumbo, A., Raje, N., et al. (2008). Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leuk Lymphoma, 49(7), 1238–1245.PubMedCrossRef

54.

Dahut, W. L., Gulley, J. L., Arlen, P. M., et al. (2004). Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. Journal of Clinical Oncology, 22(13), 2532–2539.PubMedCrossRef

55.

Petrylak D, Fizazi K, Sternberg C, Budnik N, Wit Rd WP. A phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone (DP) with or without lenalidomide in patients with castrate-resistant prostate cancer (CRPC): the MAINSAIL trial. 2012.

56.

Chott, A., Sun, Z., Morganstern, D., et al. (1999). Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. The American Journal of Pathology, 155(4), 1271–1279.PubMedCentralPubMedCrossRef

57.

Sulpice, E., Ding, S., Muscatelli-Groux, B., et al. (2009). Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells. Biology of the Cell, 101(9), 525–539.PubMedCrossRef

58.

Tsai, S., Huang, Y., Yang, W., & Tang, C. (2012). Hepatocyte growth factor-induced BMP-2 expression is mediated by c-met receptor, FAK, JNK, Runx2, and p300 pathways in human osteoblasts. International Immunopharmacology, 13(2), 156–162.PubMedCrossRef

59.

Ryan, C. J., Rosenthal, M., Ng, S., et al. (2013). Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clinical Cancer Research, 19(1), 215–224.PubMedCrossRef

60.

Kelly, W. K., Halabi, S., Carducci, M., et al. (2012). Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. Journal of Clinical Oncology, 30(13), 1534–1540.PubMedCentralPubMedCrossRef

61.

Smith, D. C., Smith, M. R., Sweeney, C., et al. (2013). Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. Journal of Clinical Oncology, 31(4), 412–419.PubMedCrossRef

62.

Isaacs, J. T., Pili, R., Qian, D. Z., et al. (2006). Identification of ABR–215050 as lead second generation quinoline–3–carboxamide anti–angiogenic agent for the treatment of prostate cancer. Prostate, 66(16), 1768–1778.PubMedCrossRef

63.

Isaacs, J. T. (2010). The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer. Expert Opinion on Investigational Drugs, 19(10), 1235–1243.PubMedCrossRef

64.

Olsson, A., Björk, A., Vallon-Christersson, J., Isaacs, J. T., & Leanderson, T. (2010). Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Molecular Cancer, 9(1), 107.PubMedCentralPubMedCrossRef

65.

Isaacs, J. T., Antony, L., Dalrymple, S. L., et al. (2013). Tasquinimod is an allosteric modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Research, 73(4), 1386–1399.PubMedCentralPubMedCrossRef

66.

Jennbacken, K., Welén, K., Olsson, A., et al. (2012). Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline–3–carboxamide tasquinimod (ABR–215050). Prostate, 72(8), 913–924.PubMedCrossRef

67.

Bratt, O., Häggman, M., Ahlgren, G., Nordle, Ö., Björk, A., & Damber, J. (2009). Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. British Journal of Cancer, 101(8), 1233–1240.PubMedCentralPubMedCrossRef

68.

Pili, R., Häggman, M., Stadler, W. M., et al. (2011). Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. Journal of Clinical Oncology, 29(30), 4022–4028.PubMedCrossRef

69.

Armstrong, A. J., Haggman, M., Stadler, W. M., et al. (2012). Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: results of long-term follow-up of a randomized phase II placebo-controlled trial. Journal of Clinical Oncology, 30(15 Suppl), 4550.

70.

Scher, H. I., Fizazi, K., Saad, F., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England Journal of Medicine, 367(13), 1187–1197.PubMedCrossRef

71.

Ryan, C. J., Smith, M. R., de Bono, J. S., et al. (2013). Abiraterone in metastatic prostate cancer without previous chemotherapy. The New England Journal of Medicine, 368(2), 138–148.PubMedCentralPubMedCrossRef

72.

Logothetis, C. J., Basch, E., Molina, A., et al. (2012). Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. The lancet oncology., 13, 1210–7.PubMedCrossRef

73.

Tran, C., Ouk, S., Clegg, N. J., et al. (2009). Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 324(5928), 787–790.PubMedCentralPubMedCrossRef

74.

Fizazi, K., Scher, H., Saad, F., et al. (2012). Impact of enzalutamide, an androgen receptor signaling inhibitor, on time to first skeletal related event (SRE) and pain in the phase 3 AFFIRM study. Annals of Oncology, 23, 295–296.CrossRef

75.

Jensen, A. B., Wynne, C., Ramirez, G., et al. (2010). The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clinical Breast Cancer, 10(6), 452–458.PubMedCrossRef

76.

Taichman, R. S. (2005). Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood, 105(7), 2631–2639.PubMedCrossRef

77.

Joyce, J. A., & Pollard, J. W. (2008). Microenvironmental regulation of metastasis. Nature Reviews Cancer, 9(4), 239–252.PubMedCentralPubMedCrossRef

78.

Aguirre-Ghiso, J. A. (2007). Models, mechanisms and clinical evidence for cancer dormancy. Nature Reviews Cancer, 7(11), 834–846.PubMedCentralPubMedCrossRef

Title: Bone-targeting agents in prostate cancer
Authors: Daniel L. Suzman
Sosipatros A. Boikos
Michael A. Carducci
Publication date: 01-09-2014
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 2-3/2014
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-013-9480-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2-3/2014

Mouse models of prostate cancer: picking the best model for the question

Clinical models and biochemical predictors of VTE in lung cancer

Circulating tumour cells—a bona fide cause of metastatic cancer

Preface

Emerging technology: applications of Raman spectroscopy for prostate cancer

Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel

Keynote webinar | Spotlight on antibody–drug conjugates in cancer